1Rockwille.FDA approves combination of avandia,insulin for type 2 diabetes[J].Case Manager,2003,14(4):21.
2Purrelo F,Rabuazza AM.Metabolic factors that affects beta cell ruction and survival[J].Diabetes Nutr Metab,2000,13(2):8491.
3Del Prato S,Marchetti P,Bonadanna RC.Phasic insulin release and metabolic regulation in type 2 diabetes[J].Diabetes,2002,51 (suppl 1):109-116.
4Plutzky J.Peroxisome proliferator-activated receptors in endothelial cell biology[J].Curr Opin Lipidol,2001,12(5):511-518.
5Bakris G,Viberti G,Weston MW,et al.Resiglitazone reduces urinary albumin excretion in type 2 diabetes[J].J Hun Hyperteus,2003,17(1):7-12.
6[1]Day C.Thiazolidinediones:a new class of antidiabetic dmgs[J].Diabet Med,1999,16(3):179-192.
7[2]Uehara G,Suzuki G,Toyoda M,et al.Glomerular expression of plateletderived growth factor PDGF A,B chain and PDGF receptor α,β in diabetic nephropathy[J].Clin Exp Nephrol,2004,8:36-42.
8[3]Yokio A,Shinji K,Noriyuki O,et al.Adipecyte derived plasma protein adiponectin acts as a platelet derived growth factor BB binding protein and regulates growth factor induced common postreceptor singnal in vascular smooth muscle cell[J].Circulation,2002,105:2893-2898.
9[4]Frscr D,Wakefild L,Phillips A,et al.Independent regulation of transforming growth factor β1,transcription and translation by glucose and platelet derived growth factor[J].Am J Pathol,2002,161:1039-1049.
10[5]Kunogi Y.Mesangia cell proliferation inhibitors for the treatment of proliferative glomerular discase[J].Med Res Rev,2003,23:15-31.
10American Diabetes Association.Summary of Revisions for the2007 Clinical Practice Recommendations Standards of MedicalCare in Diabetes[J].Diabetes Care,2007,30(1):s3-s40.
